ACTU | tickerfilter.com

Fundamental analysis

43%

Profitability 35%

Dept financing 42%

Liquidity 50%

Performance 50%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-3.44%

1 Month

14.48%

3 Months

-53.02%

6 Months

-64.86%

1 Year

-72.01%

2 Year

-70.62%

Key data

Stock price

$2.53

P/E Ratio

N/A

DAY RANGE

$2.41 - $2.95

EPS

-$1.31

52 WEEK RANGE

$1.58 - $11.99

52 WEEK CHANGE

-$71.73

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

23.710 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

1.05

PUBLIC FLOAT

AVERAGE 10 VOLUME

$360,361

AVERAGE 30 VOLUME

$196,577

Company detail

CEO: Daniel M. Schmitt
Region: US
Website: actuatetherapeutics.com
Employees: 0
IPO year: 2024

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

We are a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We were incorporated in Delaware on January 16, 2015, as Apotheca Therapeutics, Inc. and changed our name to Actuate Therapeutics, Inc. on October 1, 2015. Our principal executive offices are located at 1751 River Run, Suite 400, Fort Worth, Texas.

ACTU - ACTUATE THERAPEUTICS, INC.